Compare Recursion Pharmaceuticals Inc (RXRX) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Schlumberger NV — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Schlumberger NV trades at $46.39 (market cap $69.36B). The key difference: Schlumberger NV is far larger — about 45.3× Recursion Pharmaceuticals Inc's market cap, and Schlumberger NV pays a 2.54% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SLB | |
|---|---|---|
Market Cap | $1.53B | $69.36B |
Sector | Health | Energy |
52-Week High | $6.79 | $58.01 |
52-Week Low | $2.84 | $31.72 |
Enterprise Value | $946.50M | $77.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
